Bluebird Bio Company Profile (NASDAQ:BLUE)

About Bluebird Bio

Bluebird Bio logobluebird bio, Inc. is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder. Its oncology programs are built using lentiviral gene delivery and T cell engineering, with a focus on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. Its oncology program, bb2121, is a CAR T cell product candidate targeting B-cell maturation antigen, or BCMA, in multiple myeloma. It also offers discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: BLUE
  • CUSIP:
Key Metrics:
  • Previous Close: $72.97
  • 50 Day Moving Average: $58.81
  • 200 Day Moving Average: $48.79
  • 52-Week Range: $35.37 - $106.95
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.47
  • P/E Growth: -0.06
  • Market Cap: $2.59B
  • Outstanding Shares: 37,169,000
  • Beta: 1.9
Profitability:
  • Net Margins: -3,512.13%
  • Return on Equity: -24.85%
  • Return on Assets: -20.84%
Debt:
  • Current Ratio: 14.44%
  • Quick Ratio: 14.43%
Additional Links:
Companies Related to Bluebird Bio:

Analyst Ratings

Consensus Ratings for Bluebird Bio (NASDAQ:BLUE) (?)
Ratings Breakdown: 3 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $92.62 (34.01% upside)

Analysts' Ratings History for Bluebird Bio (NASDAQ:BLUE)
Show:
DateFirmActionRatingPrice TargetDetails
9/23/2016Jefferies GroupReiterated RatingBuy$80.00View Rating Details
9/22/2016Maxim GroupSet Price TargetBuy$85.00View Rating Details
9/22/2016Roth CapitalInitiated CoverageBuy$87.00View Rating Details
9/15/2016Goldman Sachs Group Inc.UpgradeBuy -> Conviction-Buy$135.00View Rating Details
9/11/2016BTIG ResearchReiterated RatingBuy$72.00View Rating Details
9/9/2016Cowen and CompanyReiterated RatingOutperformView Rating Details
9/9/2016Leerink SwannReiterated RatingBuyView Rating Details
9/8/2016Piper Jaffray Cos.Set Price TargetBuy$95.00View Rating Details
9/8/2016WedbushReiterated RatingOutperform$117.00View Rating Details
6/2/2016Cantor FitzgeraldInitiated CoverageHold$42.00View Rating Details
5/10/2016Janney Montgomery ScottReiterated RatingBuy$91.00View Rating Details
5/5/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
12/7/2015JPMorgan Chase & Co.DowngradeBuyView Rating Details
12/7/2015Bank of America Corp.DowngradeBuy -> Neutral$149.00 -> $102.00View Rating Details
12/7/2015Morgan StanleyDowngradeOverweight -> Equal Weight$143.00 -> $69.00View Rating Details
11/5/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$162.00View Rating Details
9/18/2015BMO Capital MarketsInitiated CoverageBuy$14.00View Rating Details
6/15/2015SunTrust Banks Inc.Reiterated RatingBuy$205.00 -> $230.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Bluebird Bio (NASDAQ:BLUE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/3/2016Q2($1.44)($1.59)$2.01 million$1.55 millionViewN/AView Earnings Details
5/4/2016Q1($1.23)($1.52)$4.50 million$1.50 millionViewN/AView Earnings Details
2/24/2016Q4($1.11)($1.29)$3.21 million$1.47 millionViewN/AView Earnings Details
8/6/2015Q215($0.78)($1.57)$8.60 million$4.94 millionViewN/AView Earnings Details
5/6/2015Q115($0.61)($0.76)$6.20 million$6.30 millionViewN/AView Earnings Details
2/25/2015Q414($0.57)($0.67)$6.20 million$6.30 millionViewN/AView Earnings Details
11/12/2014Q314($0.50)($0.61)$6.20 million$6.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.45)($0.06)$6.15 million$6.30 millionViewN/AView Earnings Details
5/13/2014Q114($0.32)($0.44)$6.23 million$6.30 millionViewN/AView Earnings Details
3/5/2014($0.31)($0.34)ViewN/AView Earnings Details
11/12/2013Q3($0.25)($0.26)$5.59 million$6.39 millionViewN/AView Earnings Details
8/8/2013Q213($0.35)($2.13)$4.85 million$6.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bluebird Bio (NASDAQ:BLUE)
Current Year EPS Consensus Estimate: $-6.18 EPS
Next Year EPS Consensus Estimate: $-6.60 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 201610($1.38)($0.92)($1.21)
Q2 201610($1.56)($0.99)($1.36)
Q3 20168($1.71)($1.28)($1.53)
Q4 20168($1.72)($1.39)($1.58)
Q1 20172($1.87)($1.62)($1.75)
Q2 20172($1.89)($1.62)($1.76)
Q3 20172($1.93)($1.63)($1.78)
Q4 20172($1.89)($1.38)($1.64)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bluebird Bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Bluebird Bio (NASDAQ:BLUE)
Insider Ownership Percentage: 3.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/13/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
8/3/2016Eric SullivanInsiderSell416$59.00$24,544.00View SEC Filing  
7/27/2016Eric SullivanInsiderSell2,912$55.01$160,189.12View SEC Filing  
7/20/2016Eric SullivanInsiderSell2,807$45.04$126,427.28View SEC Filing  
7/15/2016David DavidsonInsiderSell1,000$45.08$45,080.00View SEC Filing  
6/16/2016Philip D GregoryInsiderSell2,931$39.52$115,833.12View SEC Filing  
6/15/2016David DavidsonInsiderSell1,000$40.11$40,110.00View SEC Filing  
5/16/2016David DavidsonInsiderSell1,000$38.73$38,730.00View SEC Filing  
4/15/2016David DavidsonInsiderSell1,000$49.63$49,630.00View SEC Filing  
3/15/2016David DavidsonInsiderSell1,000$46.13$46,130.00View SEC Filing  
2/16/2016David DavidsoninsiderSell1,000$45.18$45,180.00View SEC Filing  
1/15/2016David DavidsoninsiderSell1,000$44.39$44,390.00View SEC Filing  
12/15/2015David DavidsoninsiderSell1,000$58.55$58,550.00View SEC Filing  
12/8/2015Nick LeschlyCEOBuy9,682$51.75$501,043.50View SEC Filing  
11/16/2015David DavidsoninsiderSell2,000$70.99$141,980.00View SEC Filing  
11/10/2015Jeffrey T. WalshCOOSell11,000$74.60$820,600.00View SEC Filing  
10/15/2015David DavidsoninsiderSell2,000$79.70$159,400.00View SEC Filing  
10/12/2015Jeffrey T. WalshCOOSell11,000$88.06$968,660.00View SEC Filing  
10/9/2015Jason ColeSVPSell5,000$86.91$434,550.00View SEC Filing  
10/5/2015Daniel LynchDirectorSell3,000$100.41$301,230.00View SEC Filing  
9/17/2015Daniel LynchDirectorSell1,500$140.06$210,090.00View SEC Filing  
9/15/2015David DavidsoninsiderSell2,000$129.98$259,960.00View SEC Filing  
9/10/2015Jeffrey T. WalshCOOSell11,000$130.02$1,430,220.00View SEC Filing  
9/9/2015Jason ColeSVPSell2,000$136.56$273,120.00View SEC Filing  
9/8/2015Daniel LynchDirectorSell7,000$132.75$929,250.00View SEC Filing  
9/8/2015Nick LeschlyCEOSell125,000$135.24$16,905,000.00View SEC Filing  
9/1/2015James MandellDirectorSell1,500$125.96$188,940.00View SEC Filing  
7/20/2015Eric SullivanInsiderSell1,126$163.36$183,943.36View SEC Filing  
7/15/2015David DavidsonInsiderSell2,000$165.96$331,920.00View SEC Filing  
7/10/2015Jeffrey T WalshCOOSell11,000$158.63$1,744,930.00View SEC Filing  
7/9/2015Jason ColeSVPSell5,000$158.19$790,950.00View SEC Filing  
6/15/2015David DavidsonInsiderSell2,000$183.34$366,680.00View SEC Filing  
6/10/2015Jeffrey T WalshCOOSell11,000$179.70$1,976,700.00View SEC Filing  
6/1/2015Mitchell H FinerInsiderSell15,000$190.25$2,853,750.00View SEC Filing  
4/20/2015Mitchell H FinerInsiderSell15,000$126.03$1,890,450.00View SEC Filing  
4/15/2015David DavidsonInsiderSell2,000$130.18$260,360.00View SEC Filing  
4/10/2015Jeffrey T WalshCOOSell21,000$126.21$2,650,410.00View SEC Filing  
4/2/2015Eric SullivanInsiderSell2,998$117.81$353,194.38View SEC Filing  
3/10/2015Jeffrey T WalshCOOSell10,500$110.06$1,155,630.00View SEC Filing  
3/2/2015David DavidsonInsiderSell4,000$94.84$379,360.00View SEC Filing  
1/12/2015Jeffrey T WalshCOOSell10,500$103.57$1,087,485.00View SEC Filing  
1/2/2015David DavidsonInsiderSell4,000$90.01$360,040.00View SEC Filing  
12/19/2014John MaraganoreDirectorBuy2,352$85.00$199,920.00View SEC Filing  
12/10/2014Jeffrey T WalshCOOSell43,500$78.06$3,395,610.00View SEC Filing  
12/8/2014David DavidsonInsiderSell15,000$46.10$691,500.00View SEC Filing  
12/3/2014David DavidsonInsiderSell3,000$41.65$124,950.00View SEC Filing  
12/1/2014Mitchell H FinerInsiderSell18,000$39.70$714,600.00View SEC Filing  
12/1/2014Nick LeschlyCEOSell2,417$39.70$95,954.90View SEC Filing  
11/3/2014David DavidsonInsiderSell3,000$41.68$125,040.00View SEC Filing  
11/3/2014Nick LeschlyCEOSell25,000$41.68$1,042,000.00View SEC Filing  
10/24/2014Nick LeschlyCEOSell33,900$40.22$1,363,458.00View SEC Filing  
10/10/2014Jeffrey T WalshCOOSell7,500$33.16$248,700.00View SEC Filing  
10/9/2014Steven GillisDirectorSell115,000$35.25$4,053,750.00View SEC Filing  
10/8/2014Mitchell H FinerInsiderSell34,518$33.52$1,157,043.36View SEC Filing  
10/7/2014Steven GillisDirectorSell57,435$35.43$2,034,922.05View SEC Filing  
10/2/2014Steven GillisDirectorSell91,165$35.28$3,216,301.20View SEC Filing  
10/1/2014David DavidsonInsiderSell3,000$34.55$103,650.00View SEC Filing  
10/1/2014Nick LeschlyCEOSell8,000$34.55$276,400.00View SEC Filing  
9/12/2014Robert I TepperDirectorSell125,000$36.54$4,567,500.00View SEC Filing  
9/10/2014Jeffrey T WalshCOOSell7,500$37.02$277,650.00View SEC Filing  
9/2/2014David DavidsonInsiderSell3,000$38.00$114,000.00View SEC Filing  
9/2/2014Nick LeschlyCEOSell10,300$38.45$396,035.00View SEC Filing  
8/11/2014Jeffrey T WalshCOOSell7,500$34.26$256,950.00View SEC Filing  
8/1/2014David DavidsonInsiderSell3,000$33.62$100,860.00View SEC Filing  
8/1/2014Nick LeschlyCEOSell8,000$33.62$268,960.00View SEC Filing  
7/14/2014John MaraganoreDirectorBuy2,941$34.00$99,994.00View SEC Filing  
7/10/2014Jeffrey T WalshCOOSell7,500$33.20$249,000.00View SEC Filing  
7/3/2014Nick LeschlyCEOSell22,283$39.86$888,200.38View SEC Filing  
7/1/2014David DavidsonInsiderSell3,000$39.55$118,650.00View SEC Filing  
6/20/2014Nick LeschlyCEOSell17,075$40.06$684,024.50View SEC Filing  
6/16/2014Jeffrey T WalshCOOSell1,500$39.86$59,790.00View SEC Filing  
6/16/2014Mitchell H FinerInsiderSell10,000$39.84$398,400.00View SEC Filing  
6/16/2014Nick LeschlyCEOSell42,925$40.02$1,717,858.50View SEC Filing  
6/10/2014Jeffrey T WalshCOOSell6,000$24.23$145,380.00View SEC Filing  
6/2/2014Mitchell H FinerInsiderSell8,000$22.21$177,680.00View SEC Filing  
6/2/2014Nick LeschlyCEOSell5,000$22.21$111,050.00View SEC Filing  
5/14/2014Jeffrey WalshCOOSell1,500$20.03$30,045.00View SEC Filing  
5/12/2014Jeffrey WalshCOOSell4,500$18.93$85,185.00View SEC Filing  
5/1/2014David DavidsonInsiderSell4,000$19.85$79,400.00View SEC Filing  
5/1/2014Nick LeschlyCEOSell5,000$20.07$100,350.00View SEC Filing  
4/10/2014Jeffrey WalshCOOSell6,000$21.29$127,740.00View SEC Filing  
1/22/2014Linda BainVPSell2,500$25.11$62,775.00View SEC Filing  
1/17/2014Robert TepperDirectorSell307,000$22.43$6,886,010.00View SEC Filing  
1/16/2014Mitchell FinerInsiderSell10,000$23.52$235,200.00View SEC Filing  
1/14/2014Robert TepperDirectorSell340,000$21.90$7,446,000.00View SEC Filing  
1/10/2014Jeffrey WalshCOOSell6,000$21.98$131,880.00View SEC Filing  
1/3/2014David DavidsonInsiderSell15,000$20.88$313,200.00View SEC Filing  
1/3/2014Linda BainVPSell5,000$20.89$104,450.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bluebird Bio (NASDAQ:BLUE)
DateHeadline
News IconActive biotech company shares in the news: Gilead Sciences Inc. (NASDAQ:GILD), bluebird bio, Inc. (NASDAQ:BLUE) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 26 at 4:02 PM
smarteranalyst.com logoBiotech Mixed Bag: Jefferies Weighs in on Gilead Sciences, Inc. (GILD) and bluebird bio Inc (BLUE) - Smarter Analyst (NASDAQ:BLUE)
www.smarteranalyst.com - September 24 at 8:07 AM
News IconBiotech Stocks Worth a Closer Look: bluebird bio, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 23 at 3:20 PM
News IconTwo Biotechnology Names Are Hot: PTC Therapeutics, Inc. (PTCT), bluebird bio, Inc. (BLUE) - The Independent Republic (NASDAQ:BLUE)
theindependentrepublic.com - September 23 at 3:20 PM
directorstalkinterviews.com logobluebird bio Inc 16.4% Potential Upside Now Implied by ROTH Capital - DirectorsTalk Interviews (NASDAQ:BLUE)
www.directorstalkinterviews.com - September 23 at 3:20 PM
News IconHot Biotech Stocks Recap: bluebird bio, Inc. (NASDAQ:BLUE), Tesaro, Inc. (NASDAQ:TSRO) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 23 at 3:20 PM
News IconLentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agenc... (NASDAQ:BLUE)
ih.advfn.com - September 22 at 4:02 PM
smarteranalyst.com logoBiotech Mixed Bag: Jefferies Weighs in on Gilead Sciences, Inc. (GILD) and bluebird bio Inc (BLUE) (NASDAQ:BLUE)
www.smarteranalyst.com - September 22 at 4:02 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean - PR Newswire (press release) (NASDAQ:BLUE)
www.prnewswire.com - September 22 at 8:07 AM
News IconTwo Biotechnology Names Are Hot: Exelixis, Inc. (EXEL), bluebird ... - The Independent Republic (NASDAQ:BLUE)
theindependentrepublic.com - September 21 at 3:19 PM
smarteranalyst.com logoStock Update (NASDAQ:BLUE): bluebird bio Inc Receives Access to Priority Medicines Regulatory Scheme for ... - Smarter Analyst (NASDAQ:BLUE)
www.smarteranalyst.com - September 21 at 3:19 PM
News IconTime To Put On The Watch List? - bluebird bio, Inc. (NASDAQ:BLUE), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 21 at 3:19 PM
publicnow.com logoLentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program (NASDAQ:BLUE)
www.publicnow.com - September 21 at 3:19 PM
News Icon2 Biotech Stocks News And Price Trends: bluebird bio, Inc. (NASDAQ:BLUE), Celgene Corporation (NASDAQ:CELG) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 21 at 8:25 AM
News IconActive Broker's Choice in Focus: CVS Health Corporation (NYSE ... - Street Wise Report (press release) (blog) (NASDAQ:BLUE)
streetwisereport.com - September 19 at 4:46 PM
News IconHot Biotech Stocks To Watch Right Now: bluebird bio, Inc. (BLUE), Spectrum Pharmaceuticals, Inc. (SPPI) - The Independent Republic (NASDAQ:BLUE)
theindependentrepublic.com - September 19 at 8:41 AM
News IconHC Trending Hot Stocks! TESARO Inc (TSRO), bluebird bio Inc (NASDAQ:BLUE) - share market updates (press release) (NASDAQ:BLUE)
sharemarketupdates.com - September 19 at 8:41 AM
News IconHC Stocks Highlights! Galena Biopharma Inc (GALE), bluebird bio Inc (NASDAQ:BLUE) - share market updates (press release) (NASDAQ:BLUE)
sharemarketupdates.com - September 16 at 3:50 PM
prnewswire.com logoInvestorsObserver releases covered-call reports for Alder Biopharmaceuticals, bluebird bio Inc., Expedia, Amgen and Computer Sciences Corporation (NASDAQ:BLUE)
www.prnewswire.com - September 16 at 12:24 PM
rttnews.com logoBluebird Bio Inc. (BLUE) Surged To Over A 9-Month High (NASDAQ:BLUE)
www.rttnews.com - September 16 at 12:24 PM
fool.com logoWhy Cirrus Logic, bluebird bio, and GoPro Jumped Today - Motley Fool (NASDAQ:BLUE)
www.fool.com - September 15 at 8:48 PM
fool.com logoWhy bluebird bio Inc. Jumped Again Today - Motley Fool (NASDAQ:BLUE)
www.fool.com - September 15 at 8:48 PM
News IconHot Biotech Stocks Recap: bluebird bio, Inc. (NASDAQ:BLUE), Global Blood Therapeutics, Inc. (NASDAQ:GBT) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 15 at 3:40 PM
thestreet.com logoBluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List (NASDAQ:BLUE)
www.thestreet.com - September 15 at 3:40 PM
benzinga.com logoGoldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List (NASDAQ:BLUE)
www.benzinga.com - September 15 at 12:48 PM
rttnews.com logoBluebird Bio Inc. (BLUE) Has Broken Out To A 9-Month High (NASDAQ:BLUE)
www.rttnews.com - September 15 at 12:48 PM
schaeffersresearch.com logoAnalyst Upgrades: bluebird bio Inc, Dick's Sporting Goods Inc, and Transocean LTD (NASDAQ:BLUE)
www.schaeffersresearch.com - September 15 at 12:48 PM
fool.com logoWhy bluebird bio Inc. Jumped Monday - Motley Fool (NASDAQ:BLUE)
www.fool.com - September 14 at 3:54 PM
thestreet.com logoHere's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today (NASDAQ:BLUE)
www.thestreet.com - September 14 at 3:54 PM
fool.com logoWhy bluebird bio Inc. Jumped Monday (NASDAQ:BLUE)
www.fool.com - September 13 at 8:46 AM
News IconStocks Carrying High Returns: Bristol-Myers Squibb Company (NYSE:BMY), bluebird bio, Inc. (NASDAQ:BLUE) - Street Wise Report (press release) (blog) (NASDAQ:BLUE)
streetwisereport.com - September 12 at 3:48 PM
News IconBiotech news that matter for investors: bluebird bio, Inc. (NASDAQ:BLUE), ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 12 at 3:48 PM
News IconHigh Volume Healthcare Stocks: bluebird bio, Inc. (NASDAQ:BLUE), Tesaro, Inc. (NASDAQ:TSRO) - National Daily Press (NASDAQ:BLUE)
www.nationaldailypress.com - September 10 at 8:37 AM
News IconBiotech news that matter for investors: ImmunoCellular Therapeutics, Ltd. (NYSEMKT:IMUC), bluebird bio, Inc ... - The Voice Registrar (NASDAQ:BLUE)
voiceregistrar.com - September 9 at 3:49 PM
fool.com logo3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August -- The ... - Motley Fool (NASDAQ:BLUE)
www.fool.com - September 9 at 3:49 PM
smarteranalyst.com logoCowen Weighs in on bluebird bio Inc (BLUE) Following Phase III Trial Initiation - Smarter Analyst (NASDAQ:BLUE)
www.smarteranalyst.com - September 9 at 8:45 AM
finance.yahoo.com logobluebird bio Announces Webcast of Gene Therapy Day (NASDAQ:BLUE)
finance.yahoo.com - September 9 at 8:45 AM
streetinsider.com logobluebird bio (BLUE) Opens Phase 3 Study of LentiGlobin in Patients with Transfusion-Dependent Beta-Thalassemia (NASDAQ:BLUE)
www.streetinsider.com - September 8 at 3:48 PM
smarteranalyst.com logoCompany Update (NASDAQ:BLUE): bluebird bio Inc Opens Phase 3 Study of ... (NASDAQ:BLUE)
www.smarteranalyst.com - September 8 at 3:48 PM
nasdaq.com logoBluebird Bio Inc. (BLUE) Is Climbing In Early Trade (NASDAQ:BLUE)
www.nasdaq.com - September 8 at 3:48 PM
schaeffersresearch.com logoCall Players Flock to Soaring bluebird bio Inc (BLUE) (NASDAQ:BLUE)
www.schaeffersresearch.com - September 8 at 3:48 PM
biz.yahoo.com logoBLUEBIRD BIO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:BLUE)
biz.yahoo.com - September 8 at 3:48 PM
publicnow.com logobluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia (NASDAQ:BLUE)
www.publicnow.com - September 8 at 3:48 PM
thestreet.com logoBluebird Improves Its Gene Therapy, Removing an Investor Concern (NASDAQ:BLUE)
www.thestreet.com - September 8 at 3:48 PM
finance.yahoo.com logo12:29 pm Bluebirdbio (+9%) breaks recent downtrend after opening enrollment for its Phase III study of HGB-207 treatiing petients with transfusion-dependent beta-thalassemia with non-0/0 genotypes (NASDAQ:BLUE)
finance.yahoo.com - September 8 at 3:48 PM
blogs.barrons.com logoBluebird Bio: Let the Trials Begin! (NASDAQ:BLUE)
blogs.barrons.com - September 8 at 3:48 PM
News IconStock Sliding Down Over the Last Month: bluebird bio, Inc ... - Post News (NASDAQ:BLUE)
www.kentuckypostnews.com - September 8 at 7:59 AM
benzinga.com logoBluebird Heading Into 'Catalyst-Rich' Second Half Of The Year - Benzinga (NASDAQ:BLUE)
www.benzinga.com - September 7 at 8:57 PM
prnewswire.com logoOncorus®, Inc. Appoints Biotech Industry Veteran Cyrus D. Mozayeni, M.D., as President and Chief Business Officer - PR Newswire (press release) (NASDAQ:BLUE)
www.prnewswire.com - September 7 at 8:57 PM
benzinga.com logoBluebird Heading Into 'Catalyst-Rich' Second Half Of The Year (NASDAQ:BLUE)
www.benzinga.com - September 7 at 3:52 PM

Social

Bluebird Bio (NASDAQ:BLUE) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff